Anamorelin dosage by bodyweight
Reference dose ranges scaled across bodyweight bands, anchored to the most-cited research dose (100000 mcg @ 75 kg). Educational only, never a recommendation.
| Bodyweight band | Reference dose range | At U-100 (1 mg/mL) | Vol. on U-100 (5 mg / 2 mL) | 5× t½ elapsed |
|---|---|---|---|---|
| <60 kg / <132 lb | 62333–84333 mcg | 62.33–84.33 mL | 2493–3373 units24.93–33.73 mL | – |
| 60–75 kg / 132–165 lb | 76500–103500 mcg | 76.50–103.50 mL | 3060–4140 units30.60–41.40 mL | – |
| 75–90 kg / 165–198 lb | 93500–126500 mcg | 93.50–126.50 mL | 3740–5060 units37.40–50.60 mL | – |
| 90–105 kg / 198–231 lb | 110500–149500 mcg | 110.50–149.50 mL | 4420–5980 units44.20–59.80 mL | – |
| >105 kg / >231 lb | 127500–172500 mcg | 127.50–172.50 mL | 5100–6900 units51.00–69.00 mL | – |
Volume column assumes a standard 5 mg vial reconstituted with 2 mL bacteriostatic water (concentration 2.5 mg/mL); insulin units shown for a U-100 syringe. No published half-life on file for Anamorelin; the elapsed-time column is hidden.
Anamorelin by goal
Read Anamorelin's profile and dosing through a specific research-goal lens.
Dose & PK references
Selected from the Anamorelin bibliography for relevance to dosing and pharmacokinetics.
- Efficacy and safety of anamorelin for cancer cachexia in patients with unresectable or recurrent gastric cancer: a multicentre, open-label, randomised controlled trial
- Anamorelin in the Management of Cancer Cachexia: Clinical Efficacy, Challenges, and Future Directions
- Effects of the ghrelin receptor agonist anamorelin on lean body mass in cancer patients with cachexia; results from a Phase II randomized, double blind, multicenter study
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.